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Relationship Between an Activated N-ras Oncogene and Chromosomal
Abnormality During Leukemic Progression From Myelodysplastic Syndrome
By Hisamaru Hirai, Michiko Okada, Hideaki Mizoguchi, Hiroyuki Mano, Yukio Kobayashi,
Junji Nishida, and Fumimaro Takaku
The relationship between chromosomal abnormality and
oncogene activation was investigated during leukemic pro-
gression in two patients with myelodysplastic syndrome
(MDS). Both patients had partial or complete deletion of
chromosome 5 in metaphase cells obtained throughout the
progression to leukemia. Analysis with specific oligonu-
cleotide probes revealed that bone marrow cells containing
an activated N-ras oncogene proliferated in a dominant
O NE of the prominent recent developments in leukemia
research has been the identification of specific point
mutation in the N-ras gene in human leukemia cells.’6
Activation of the N-ras gene by somatic mutation is now
considered to be a critical step in the genetic basis of human
leukemogenesis. Although activated N-ras oncogenes have
been found in a significant percentage of human leukemias,
it has not been demonstrated that activation of the N-ras
oncogene alone causes pathogenesis of human leukemias.
It has been suggested that the development of leukemia in
patients with myelodysplastic syndrome (MDS) may be
related to chromosomal abnormalities or genetic altera-
tions.7’4 Some specific chromosomal abnormalities are
thought to be related to the pathogenesis of MDS.7’3 Recent-
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manner during the process of leukemic conversion in both
patients. These observations suggest that the chrome-
somal abnormality may precede activation of the N-ras
gene in these patients. and that both the chromosomal
abnormality and the activated N-ras oncogene contribute
to the development of leukemia.
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ly, we detected a mutation at codon I 3 of the N-ras gene in
bone marrow cells from three patients with MDS.’4 In the
present study, we investigated the relationship between
abnormalities in chromosome 5 and activation of the N-ras
gene during leukemic progression from MDS in two of these
three patients.
MATERIALS AND METHODS
Sources of DNA. Bone marrow cells were collected from two
MDS patients: one with refractory anemia (RA) and the other with
RA with excess of blasts (RAEB) at first diagnosis. The diagnosis of
MDS fulfilled the criteria of the French-American-British (FAB)
classification.’5 Clinical characteristics of patients at the time of
sampling of marrow cells are shown in Table I . Normal marrow cells
from healthy volunteers were obtained with informed consent and
were examined as normal controls.
Synthetic oligonucleotide probes. Synthesis of oligonucleotide
probes was carried out as described.’4 The probes Nl3-lC (5’-
GGAGCAGGTCGTGTTGGGAA-3’) and N6 I -wt (5’-
TACTCTTCTTGTCCAGCTGT-3’) were synthesized using a 20-
mer synthetic template and a 8-nucleotide (mer) primer complemen-
tary to the 3’ end of the 20-mer. This primer-template mixture was
incubated with [a-32P]dGTP, [a-32P]dTTP, cold dCTP and dATP,
and DNA polymerase I (Klenow fragment).
Direct gel hybridization. High molecular weight DNAs were
extracted from buffy coat cells of heparinized marrow. Twenty
micrograms of DNA were digested with PstI and electrophoresed on
0.5% agarose gels. Gels were denatured in 0.4 mol/L NaOH, 0.8
mol/L NaCI, neutralized in 0.5 mol/L Tris-HCI (pH 7.4), 1.5
mol/L NaC1, and dried. Dried gels were then hybridized at 53#{176}C
with the N13-lC probe or at 50#{176}C with the N61-wt probe in 5 x
SSPE (I x SSPE is 10 mmol/L sodium phosphate (pH 7.0), 0.18
mol/L NaC1, I mmol/L EDTA), 0.3% SDS and 10 zg/mL
sonicated salmon sperm DNA. Hybridized gels were washed in 2 x
Table 1 . Clinical Characteristics at the Time of Samplin g of Bone M arrow Cells
Case Age/Sex
. Peripheral Blood
Disease
.
Sample Dtsat,on Hb WBC Platelet
No. (mo) (g/dL) (/￿aL) (x iO4/￿L)
Bone Marrow
Cellularity Blast (%) Cytogenetics
RA 34/M 1 30 6.0 2.200 10.9
2 40 6.3 1,200 6.3
3 44 6.1 11,600 2.1
H
H
H
5 46XY.5q- (25/25)
i5 46XY,5q- (28/30)
50 46XY.5q- (19/19)
RAEB 54/M 1 1 1 8.2 2.600 7.4
2 17 8.3 1.600 2.5
3 20 5.9 104.600 1.4
N
H
H
9 44XY. - 5, - 17 (18/20)
25 NT
52 44XY,-5,-17(15/15)
Abbrevi ations: H, hyp ercellular; N. normocellular; 5q- , del(5)(q15q33); NT, not tested.
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Fig 1 . Hybridization of synthetic oligonucleotide probes to
DNAs of bone marrow cells from two patients with RA or RAEB.
Sample numbers are identical to those in Table 1 . Normal human
DNA (N) was used as a control.
SSPE, 0.1% SDS at room temperature, in 5 x SSPE, 0.1% SDS at
53#{176}C for 15 minutes, and finally in the same solution at 63#{176}C for the
N13-1C probe or at 59#{176}C for the N61-wt probe for five minutes. Gel
membranes were autoradiographed for three to five days using
intensifying screens. Hybridized mutated N-ras bands were quanti-
tated by scanning the autoradiogram with a densitometer.
Cytogenetic studies. Chromosome analysis was performed on
synchronized or unsynchronized cultures from each bone marrow
sample using a Q-banding technique. The synchronization method
with methotrexate for a routine air-drying technique has been
RESULTS
The N-ras gene of both cases presented here was found to
contain a point mutation from 0 to C at the first letter of
codon 13, using an in vivo selection assay in nude mice with
transfected NIH3T3 cells as described.’4 In the present
studies, the point mutation was detected in bone marrow cell
DNA by hybridization with oligonucleotide N13-1C. This
N 13- 1C probe encompasses the sequence around mutant
codon 13, and hybridized only to mutant DNA under high
stringency conditions. Bone marrow cell DNA was prepared
from both patients at different stages of leukemic pro-
gression, and probed with N13-lC (Fig 1). In both cases, the
N 13-IC probe failed to give a clear hybridizing signal in the
first sample, but the strength of the signal increased signifi-
cantly in samples 2 and 3. The data were quantitated by
densitometry, and the results are plotted in Fig 2. These
results suggest that the intensity of the hybridizing signal is
proportional to the percentage of blasts in each case, since
the internal control N6l-wt probe, corresponding to the
normal sequence of the N-ras gene surrounding codon 61,
hybridized equally well to DNA from all samples. These
observations indicate that proliferative blast cells contain the
point mutation at codon 1 3 of the N-ras oncogene.
DISCUSSION
Partial or complete loss of chromosome 5 has been
observed in patients with RA or with acute nonlymphocytic
Fig 2. Quantitation of mutant N-ras DNA hybridized with the
N13-1 C probe. Signals shown in Fig 1 were quantitated by
densitometric scanning. Data are expressed in relative units as a
percentage of the sample 3 in the case RAEB. Closed circle. the RA
case; open circle. the RAEB case.
leukemia arising either de novo or secondary to cytotoxic
therapy for a previous malignant disease.7’3’724 The varia-
bility of the breakpoints noted in the deletion of chromosome
5 suggests that the event underlying malignant transforma-
tion is the loss of a critical DNA sequence rather than the
consistent juxtaposition of two genes (as in the case of c-abl
and bcr in chronic myelogenous leukemia.25). Partial loss of
chromsome 5 is considered to be necessary but not sufficient
for malignant transformation, although patients with a sin-
gle 5q- tend to have a mild course and cases with a combined
deletion 5 have a relatively poor prognosis.’2”3’24 Thus, an
additional event is considered to have a role in transforma-
tion to acute nonlymphocytic leukemia.
In our two cases, the deletion of part or all of chromosome
5 has been observed in metaphase cells from early stages of
the disease, indicating that the chromosomal deletion may
provide a growth advantage to the bone marrow cells. Our
studies with transfection assay’4 and oligonucleotide hybrid-
ization (Figs 1 and 2) suggest that the second event in
leukemic progresssion is the activation of the N-ras gene in
one or a small number of cells. These results indicate that the
activated N-ras oncogene is contributing in a dominant
manner to the process of leukemic progression from MDS.
Thus, developed leukemic cells were found to contain both
the abnormality of chromosome 5 and the point mutation of
an N-ras gene. It seems likely that activation of the N-ras
oncogene probably occurs after initiation of leukemogenesis.
These observations demonstrate potential relationships
between chromosomal abnormality and oncogene activation,
and provide insight into the nature of leukemogenesis in
other leukemia cases with chromosomal abnormalities.
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